Comparison of stage III mucinous and serous ovarian cancer: a case-control study

Table 2 Univariate and multivariate analyses for overall survival in the entire cohort (stage III mucinous [n = 81] and serous [n = 162] ovarian carcinoma)

	Univariate analysis OS^a N of events (%)	p	Multivariateanalysis
	Univariate analysis OS^a N of events (%)	p	HR	CI 95%	p
Age, y
< 52	36/118 (61.7%)	0.163
≥ 52	47/125 (56.7%)	0.163
Menopausal Status
Premenopausal	33/96 (56.6%)	0.89
Postmenopausal	50/147 (60.5%)	0.89
Ca-125(IU/ml)
< 310	46/121 (56.2%)	0.089
≥ 310	37/122 (62.2%)	0.089
Grade
1	33/87 (55.1%)	0.74
2–3	50/156 (61.5%)	0.74
Ascites
Present	62/167 (56.2%)	0.371
Absent	21/76 (66%)	0.371
Retroperitoneal LN metastases
Present	44/112 (39.2%)	0.646
Absent	55/131 (41.9%)	0.646
Peritoneal cytology
Positive	73/198 (56.5%)	0.215
Negative	10/45 (71.8%)	0.215
Stage
IIIA1	6/39 (78.4%)	0.001
IIIA2, IIIB, IIIC	77/204 (55.6%)	0.001
Appendiceal Involvement
Present	41/88 (45%)	< 0.001
Absent	42/155 (66.9%)	< 0.001
Omental Involvement
Present	71/174 (52%)	< 0.001
Absent	12/69 (77.6%)	< 0.001
Peritoneal Involvement
Present	67/160 (49.2%)	< 0.001	2.39	1.38–4.14	0.002
Absent	16/83 (76.9%)	< 0.001	2.39	1.38–4.14	0.002
Histologic Subtype
Mucinous	41/81 (44.9%)	< 0.001	2.28	1.53–3.40	< 0.001
Serous	42/162 (66.3%)	< 0.001	2.28	1.53–3.40	< 0.001

^a:5-year overall survival rate
Abbreviations: OS Overall Survival, LN Lymph node, HR Hazard ratio, CI Confidence interval, y Year, N number

ISSN: 1757-2215